Thanks for emailing that article!
The Glaucoma 360 Annual Gala at San Francisco’s historic Palace Hotel honored leaders in glaucoma research innovation and visionary volunteers helping to raise awareness.
The benefit event on February 2nd included a reception, dinner, live auction, silent auction, and a special musical performance — altogether this year’s Gala raised $520,000 to support Glaucoma Research Foundation’s innovative research and education programs.
The Gala included presentation of The 2017 Catalyst Award to Eugene de Juan Jr., MD in recognition of his outstanding leadership and commitment to advancing ophthalmology. Dr. de Juan is the Founder and Vice-Chairman of ForSight Labs in Menlo Park, California, and the Jean Kelly Stock Distinguished Professor of Ophthalmology at the University of California, San Francisco.
The Visionary Award was presented to Janette Márquez, a talented and accomplished opera singer who is blind from congenital glaucoma. Ms. Márquez gave an inspirational performance and received a standing ovation from the audience of almost 400 in attendance.
Glaucoma 360 comprises three days of events uniting research, industry, and philanthropy to prevent vision loss from glaucoma and speed the cure. The 6th Annual New Horizons Forum took place on February 3rd. This full-day catalyst meeting was designed to bring together essential components and key opinion leaders to speed the translation of new and innovative ideas into clinical practice. Leading doctors, scientists, and business people from various clinical, industry, financial, and government organizations assembled in a unique exchange on research innovation and how to accelerate advances in glaucoma treatment.
Dr. Karim Damji of the University of Alberta described his experience at this year’s New Horizons Forum as “a simply outstanding experience to learn about cutting edge innovations in glaucoma diagnosis and management while connecting with like-minded colleagues and prospective industry partners.” Another forum participant, Dr. Malik Kahook from the University of Colorado School of Medicine, said: “New Horizons is a unique meeting that brings together clinicians, industry members, and patients for an open discussion about the treatment of glaucoma today and in the future.”
Sessions at New Horizons included innovations in glaucoma pharmaceuticals, drug delivery, and devices, as well as industry, FDA and venture capital discussion panels. The Keynote lecture was delivered by Joel S. Schuman, MD, FACS, Chair of the Department of Ophthalmology at New York University’s Langone Medical Center, on the topic of Optical Coherence Tomography—Past, Present, and Future. Jeffrey L. Goldberg, MD, PhD, Professor and Chair of Ophthalmology at the Byers Eye Institute at Stanford University presented an update on the Catalyst for a Cure Biomarker Initiative, funded by GRF, which seeks new treatment targets for glaucoma.
Catalyst Circle level donors receive complimentary registration for the New Horizons Forum. Pat Rospenda, whose granddaughter has glaucoma, attended the meeting for the first time. She noted: “The ability to speak to the doctors and scientists who are on the front lines was especially helpful. Meeting these talented people and listening how passionately committed they are gives us a great sense of hope that they will have victory over glaucoma. It is so good to know we are not alone.”
Following the Gala and New Horizons, Glaucoma 360 continued (day 3) with two half-day meetings for practicing ophthalmologists and optometrists, highlighting the latest advances in glaucoma, with detailed information about medications, diagnostic challenges, and surgical technique. A faculty of specialists in glaucoma diagnosis and treatment imparted wisdom and helpful tips to their colleagues in these unique continuing education courses designed to help the doctors who are helping the glaucoma patients.
Founded in 2012 by Adrienne Graves, PhD and Andrew G. Iwach, MD, the leadership for Glaucoma 360 includes nationally and internationally respected pioneers in the field of glaucoma, business, and medical innovation.
Last reviewed on October 29, 2017
This article appeared in the May 2017 issue of Gleams.Subscribe